The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

Clesrovimab joins the monoclonal antibody nirsevimab (Beyfortus), as well as the maternal bivalent RSV prefusion F protein ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Early Phase I results for JNJ-79635322 demonstrated an 86.1% overall response rate in heavily pretreated multiple myeloma ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya ...

HHS Secretary Robert F. Kennedy Jr. abruptly removed 17 vaccine experts from the CDC’s Advisory Committee on Immunization ...

The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

AbTherx's highly efficient research planning and partnering process enabled Wield, an early-stage startup, to achieve concept-to-collaboration within weeks MOUNTAIN VIEW, CA / ACCESS Newswire / June 1 ...

PDUFA date of June 13th 2025 by which FDA will decide upon whether or not UGN-102 should be approved for patients with ...